Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
178actual
Sites
13
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-12 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-01 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving Functional Disability Scale (FDS) Score of =0, no disability, able to function normally 4 hours post-dose
measured Up to approximately 12 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed